Similar articles

Abstract: Histological low-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia grade 1 (LSIL/CIN1) preceded by normal or mildly abnormal cytology is recommended for conservative follow-up, with no separated management. In this study, we assessed the triage value of human papillomavirus (HPV) 16/18 genotyping in 273 patients with LSIL/CIN1. HPV16/18 genotyping was performed at baseline and follow-up was at 6-monthly intervals for up to 2 years. At each follow-up, women positive for cytology or high-risk HPV (hrHPV) were referred for colposcopy. Enrollment cytology, HPV16/18 genotyping, and questionnaire-obtained factors were linked to the 2-year cumulative progression rate. Univariate and multivariate analyses were performed taking into account time-to-event with Cox proportional hazard regression. The results showed that 190 cases (69.6%) regressed, 37 (13.6%) persisted, and 46 (16.8%) progressed. HPV16/18 positivity (hazard ratio (HR), 2.708; 95% confidence interval (CI), 1.432–5.121; P=0.002) is significantly associated with higher 2-year cumulative progression rate. Sub-analysis by enrollment cytology and age restricted the positive association among patients preceded by mildly abnormal cytology and aged 30 years or older. Immediate treatment is a rational recommendation for the high-risk subgroup, when good compliance is not assured.

人乳头瘤病毒16/18分型在细胞学轻度异常的低度宫颈病变中的预测价值

[1]Bosch, F.X., Burchell, A.N., Schiffman, M., et al., 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine, 26(Suppl. 10):K1-K16.

[2]Bulk, S., Bulkmans, N.W., Berkhof, J., et al., 2007. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int. J. Cancer, 121(2):361-367.

[3]Bzhalava, D., Guan, P., Franceschi, S., et al., 2013. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology, 445(1-2):224-231.

[4]Castle, P.E., Stoler, M.H., Wright, T.C.Jr., et al., 2011. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol., 12(9):880-890.

[5]Dahlström, L.A., Ylitalo, N., Sundström, K., et al., 2010. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int. J. Cancer, 127(8):1923-1930.

[6]Darragh, T.M., Colgan, T.J., Cox, J.T., et al., 2012. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch. Pathol. Lab. Med., 136(10):1266-1297.

[7]Davey, D.D., Goulart, R., Nayar, R., 2014. 2013 statement on human papillomavirus DNA test utilization. Am. J. Clin. Pathol., 141(4):459-461.

[8]de Sanjose, S., Quint ,W.G., Alemany, L., et al., 2010. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol., 11(11):1048-1056.

[9]Grisaru, D., Avidor, B., Niv, J., et al., 2008. Pilot study of prevalence of high-risk human papillomavirus genotypes in Israeli Jewish women referred for colposcopic examination. J. Clin. Microbiol., 46(5):1602-1605.

[10]Huang, E.C., Tomic, M.M., Hanamornroongruang, S., et al., 2016. p16ink4 and cytokeratin 7 immunostaining in predicting HSIL outcome for low-grade squamous intraepithelial lesions: a case series, literature review and commentary. Mod. Pathol., 29(12):1501-1510.

[11]Kang, W.D., Ju, U.C., Kim, S.M., 2016. A human papillomavirus (HPV)-16 or HPV-18 genotype is a reliable predictor of residual disease in a subsequent hysterectomy following a loop electrosurgical excision procedure for cervical intraepithelial neoplasia 3. J. Gynecol. Oncol., 27(1):e2.

[12]Katki, H.A., Gage, J.C., Schiffman, M., et al., 2013. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. J. Low Genit. Tract Dis., 17(5 Suppl. 1):S69-S77.

[13]Khan, M.J., Castle, P.E., Lorincz, A.T., et al., 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst., 97(14):1072-1079.

[14]Lagos, M., van de Wyngard, V., Poggi, H., et al., 2015. HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile. Infect. Agents Cancer, 10:43.

[15]Li, N., Franceschi, S., Howell-Jones, R., et al., 2011. Human papillomavirus type distribution in 30 848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer, 128(4):927-935.

[16]Liao, G.D., Sellors, J.W., Sun, H.K., et al., 2014. p16^INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China. Int. J. Cancer, 134(7):1715-1724.

[17]Liu, S.S., Leung, R.C., Chan, K.K., et al., 2010. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay. J. Clin. Microbiol., 48(3):758-764.

[18]Martin, C.M., O'Leary, J.J., 2011. Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract. Res. Clin. Obstet. Gynaecol., 25(5):605-615.

[19]Massad, L.S., Einstein, M.H., Huh, W.K., et al., 2013. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet. Gynecol., 121(4):829-846.

[20]McKenna, M., McMenamin, M.M., 2014. Human papillomavirus testing in young women: clinical outcomes of human papillomavirus triage in a UK cervical screening program. Cancer Cytopathol., 122(9):702-710.

[21]McKenna, M., McMenamin, M., McDowell, A., 2016. HPV16 and HPV18 genotyping triage in young women with borderline cytology or mild dyskaryosis: effect of age on genotype-specific risk of high-grade CIN. Cytopathology, 27(4):261-268.

[22]Mills, A.M., Paquette, C., Castle, P.E., et al., 2015. Risk stratification by p16 immunostaining of CIN1 biopsies: a retrospective study of patients from the quadrivalent HPV vaccine trials. Am. J. Surg. Pathol., 39(5):611-617.

[23]Paquette, C., Mills, A.M., Stoler, M.H., 2016. Predictive value of cytokeratin 7 immunohistochemistry in cervical low-grade squamous intraepithelial lesion as a marker for risk of progression to a high-grade lesion. Am. J. Surg. Pathol., 40(2):236-243.

[24]Persson, M., Elfström, K.M., Olsson, S.E., et al., 2015. Minor cytological abnormalities and up to 7-year risk for subsequent high-grade lesions by HPV type. PLoS ONE, 10(6):e0127444.

[25]Rijkaart, D.C., Berkhof, J., Rozendaal, L., et al., 2012. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol., 13(1):78-88.

[26]Rodriguez, A.C., Schiffman, M., Herrero, R., et al., 2008. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J. Natl. Cancer Inst., 100(7):513-517.

[27]Sagasta, A., Castillo, P., Saco, A., et al., 2016. p16 staining has limited value in predicting the outcome of histological low-grade squamous intraepithelial lesions of the cervix. Mod. Pathol., 29(1):51-59.

[28]Schiffman, M., Castle, P.E., Jeronimo, J., et al., 2007. Human papillomavirus and cervical cancer. Lancet, 370(9590):890-907.

[29]Solomon, D., Davey, D., Kurman, R., et al., 2002. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA, 287(16):2114-2119.

[30]Tjalma, W.A., Fiander, A., Reich, O., et al., 2013. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int. J. Cancer, 132(4):854-867.

[31]Walboomers, J.M., Jacobs, M.V., Manos, M.M., et al., 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol., 189(1):12-19.

[32]Wheeler, C.M., Hunt, W.C., Cuzick, J., et al., 2014. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: a population-based study of opportunistic cervical screening in the United States. Int. J. Cancer, 135(3):624-634.

[33]Wright, T.C.Jr., Stoler, M.H., Sharma, A., et al., 2011. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am. J. Clin. Pathol., 136(4):578-586.

[34]Ye, J., Cheng, X., Chen, X., et al., 2010a. Prevalence and risk profile of cervical human papillomavirus infection in Zhejiang Province, southeast China: a population-based study. Virol. J., 7:66.

[35]Ye, J., Cheng, X., Chen, X., et al., 2010b. Short-term type-specific HPV persistence and its predictors in an asymptomatic general female population in Zhejiang, China. Int. J. Gynecol. Obstet., 110(3):217-222.